Fasciitis is an inflammatory disease of the fascia, the thick tissue between muscles and between tendons, which results in inflammation (swelling) and tissue death. It tends to affect the hips and legs, but often occurs in other locations of the body. It tends to appear as red and swollen, with pain and weakness. It is usually treated medically and sometimes resolves on its own.
A cause for this most common disorder of the great toe is elusive. The patient must be questioned about any possible local trauma, infection and malignancy of the heel/tarsus, to look for an underlying cause.
Fasciitis is best treated with a multidisciplinary program that includes medication or surgery and can be cured. The diagnosis and treatment of Fasciitis at a tertiary care level can make a lasting change (P<0.0001).
The most common signs of fasciitis include pain and swelling at the site of the compression of the fascia. Other common symptoms include fever, chills, generalized pains and redness of the affected muscle. The clinical presentation of fasciitis will often lead to the initial diagnosis of other conditions. While it is necessary to know the diagnosis of fasciitis when evaluating the signs of the disease, one specific sign of fasciitis is the "sausage-redness" of a localized area of the skin. This is a sign of local inflammation in the fascia. This sign may occur when a person has local trauma, but also if there is a disease process that leads to inflammation of the fascia.
Fasciitis occurs in 3.5 per 100,000 hospital visits per year. Overall, the incidence of fasciitis was highest among patients 25-34 years of age. There was no association between fasciitis and race, sex, or the presence of psoriasis.
If antibiotics are administered early, healing occurs in nearly two thirds of cases while if antibiotics are administered later, fasciitis presents is almost invariably recalcitrant.
We suggest consideration of using clinical trials for fasciitis in those presenting with a history or physical examination findings suggestive of fasciitis, and those with a significant degree of pain despite treatment with analgesics. Future investigation could focus on which type of treatment to use, on defining and standardizing treatment dosing as a component of clinical trials for fasciitis.
There was no significant effect on the FasL, Fas or FasL+cells, and therefore it seems unlikely to have been due to FasL upregulation. The data are consistent with the hypothesis that glasdegib acts to reduce the apoptotic rate of faspositive cell and increase the number of CD95-expressing cells, which are involved with FasL-induced apoptosis. The data also demonstrates that FasL and CD95 expression remain unchanged.
Glasdegib has shown efficacy as a single agent monotherapy for recalcitrant osteomyelitis and is generally well tolerated. This open, multicenter, pilot study suggests that glasdegib is an effective treatment for recalcitrant diabetic foot osteomyelitis.
A variety of conditions can benefit from Gla treatment, but it is commonly used to treat a group of conditions that are frequently associated with pain and swollen joints: a syndrome known as Gouty Acute Spondylo Arthritis. Specifically, Gla treatment is given for two conditions that represent the pain and swelling of Gouty Acute Spondylo Arthritis: Ankle Gout and Hidradenitis Plástica. Gla is also given in the treatment of various types of arthritis, which are conditions associated with pain and inflammation in other bones and joints, as well as arthritis-related inflammation in the joints. Gla is sometimes used in combination with chemotherapy to treat leukemia.